Back to Stocks

TOMZ

TOMI Environmental Solutions, Inc.
8 filings tracked
healthcaremedical devicesMICRO (<$300M)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

TOMI Environmental Solutions is demonstrating a strategic shift toward a high-margin, recurring revenue model.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the narrative of growth, TOMI's financial foundation remains precarious, as evidenced by a formal going concern warning. The company reported a net loss of $810,000 for the quarter and maintains a staggering accumulated deficit of $58.9 million.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every TOMZ filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing reveals a company at a critical crossroads, balancing an accelerating commercial trajectory against a failing balance sheet. On one hand, the sequential revenue jump and international regulatory wins suggest that the SteraMist technology has genuine market fit and scalability. On the other hand, the financial metrics describe a distressed entity struggling with solvency, characterized by a minimal equity base and a reliance on high-cost debt. The overall impact of the filing is a high-risk, high-reward scenario. The potential merger with Carbonium Core and the conversion of the $4.3 million project pipeline could provide the necessary pivot to stability. However, the immediate threat of Nasdaq delisting and the ongoing cash burn mean that the window for execution is narrow. Investors are essentially betting on whether the commercial momentum can outpace the liquidity crisis before the company is forced into further drastic dilution or insolvency.

Selected Quarter

Core Takeaway

TOMI is successfully scaling its product adoption and international footprint, but it is currently operating with critically low cash reserves and high-interest debt.

Investor Lens

The trade-off is between the potential for a massive valuation re-rating via the Carbonium Core merger and the very real possibility of total equity wipeout due to insolvency.

Watch Next

The closing of the Carbonium Core merger and the May 18, 2026, Nasdaq compliance deadline.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)-0.25Q1 '26 (10-K)-0.25Q2 '26 (10-Q)

Signal Timeline

28 of 32
Active Filters:Quarter: Q2 '26 (10-Q)
bearishMay 8

Gross margin dropped from 60% to 50% due to strategic discounting and product mix shift.

margin compression
70%
neutralMay 8

Reliance on $20M ELOC and shelf registration to maintain minimal liquidity.

capital raise
50%
bearishMay 8

Net loss of $810k and formal going concern warning due to severe capital deficiency.

earnings miss
90%
bullishMay 8

Non-binding LOI to merge with Carbonium Core implying a $120M enterprise valuation.

acquisition
60%
bearishMay 8

Gross margin dropped from 60% to 50% due to strategic discounting and product mix shift.

margin compression
70%
neutralMay 8

Reliance on $20M ELOC and shelf registration to maintain minimal liquidity.

capital raise
50%
bearishMay 8

Net loss of $810k and formal going concern warning due to severe capital deficiency.

earnings miss
90%
bullishMay 8

Non-binding LOI to merge with Carbonium Core implying a $120M enterprise valuation.

acquisition
60%
bearishMay 8

Gross margin dropped from 60% to 50% due to strategic discounting and product mix shift.

margin compression
70%
neutralMay 8

Reliance on $20M ELOC and shelf registration to maintain minimal liquidity.

capital raise
50%
bearishMay 8

Net loss of $810k and formal going concern warning due to severe capital deficiency.

earnings miss
90%
bullishMay 8

Non-binding LOI to merge with Carbonium Core implying a $120M enterprise valuation.

acquisition
60%
bearishMay 8

Gross margin dropped from 60% to 50% due to strategic discounting and product mix shift.

margin compression
70%
neutralMay 8

Reliance on $20M ELOC and shelf registration to maintain minimal liquidity.

capital raise
50%
bearishMay 8

Net loss of $810k and formal going concern warning due to severe capital deficiency.

earnings miss
90%
bullishMay 8

Non-binding LOI to merge with Carbonium Core implying a $120M enterprise valuation.

acquisition
60%
bearishMay 8

Gross margin dropped from 60% to 50% due to strategic discounting and product mix shift.

margin compression
70%
neutralMay 8

Reliance on $20M ELOC and shelf registration to maintain minimal liquidity.

capital raise
50%
bearishMay 8

Net loss of $810k and formal going concern warning due to severe capital deficiency.

earnings miss
90%
bullishMay 8

Non-binding LOI to merge with Carbonium Core implying a $120M enterprise valuation.

acquisition
60%
bearishMay 8

Gross margin dropped from 60% to 50% due to strategic discounting and product mix shift.

margin compression
70%
neutralMay 8

Reliance on $20M ELOC and shelf registration to maintain minimal liquidity.

capital raise
50%
bearishMay 8

Net loss of $810k and formal going concern warning due to severe capital deficiency.

earnings miss
90%
bullishMay 8

Non-binding LOI to merge with Carbonium Core implying a $120M enterprise valuation.

acquisition
60%
bearishMay 8

Gross margin dropped from 60% to 50% due to strategic discounting and product mix shift.

margin compression
70%
neutralMay 8

Reliance on $20M ELOC and shelf registration to maintain minimal liquidity.

capital raise
50%
bearishMay 8

Net loss of $810k and formal going concern warning due to severe capital deficiency.

earnings miss
90%
bullishMay 8

Non-binding LOI to merge with Carbonium Core implying a $120M enterprise valuation.

acquisition
60%

Filing History

10-QMay 8, 2026
Expand Sequence

The Q1 2026 filing reveals a company at a critical crossroads, balancing an accelerating commercial trajectory against a failing balance sheet. On one hand, the sequential revenue jump and international regulatory wins suggest that the SteraMist technology has genuine market fit and scalability. On the other hand, the financial metrics describe a distressed entity struggling with solvency, characterized by a minimal equity base and a reliance on high-cost debt. The overall impact of the filing is a high-risk, high-reward scenario. The potential merger with Carbonium Core and the conversion of the $4.3 million project pipeline could provide the necessary pivot to stability. However, the immediate threat of Nasdaq delisting and the ongoing cash burn mean that the window for execution is narrow. Investors are essentially betting on whether the commercial momentum can outpace the liquidity crisis before the company is forced into further drastic dilution or insolvency.

10-KMar 31, 2026
Expand Sequence

The 2025 10-K paints a picture of a company at a crossroads, where cutting-edge technology and strong commercial interest are clashing with a fragile balance sheet. On one hand, the expansion into aerospace, aquaculture, and the food safety sector suggests that the SteraMist technology has broad, scalable utility. The shift toward an OEM-integrated model is a logical evolution to capture recurring revenue and reduce the friction of individual equipment sales. However, these strategic wins are currently overshadowed by a liquidity crisis that threatens the company's very existence. For investors, the central tension is whether the $20 million equity line of credit and the $18 million pipeline can be converted into cash fast enough to avoid delisting and insolvency. The improvement in gross margins is a positive signal, but it is insufficient to offset the operational burn. The company's survival depends entirely on its ability to execute the conversion of its integration projects into recognized revenue while navigating the strict requirements of the Nasdaq listing board. Ultimately, TOMI is a high-risk, high-reward play on the future of biosecurity infrastructure.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.